Microangiopathic Hemolytic Anemia

Microangiopathic hemolytic anemia (MAHA) is a form of hemolytic anemia characterized by mechanical fragmentation of red blood cells (RBCs) as they traverse small blood vessels that are partially occluded by fibrin thrombi, endothelial damage, or intravascular devices. The hallmark of MAHA is the presence of schistocytes (fragmented RBCs) on the peripheral blood smear, along with thrombocytopenia and often evidence of end-organ ischemia. In veterinary medicine, MAHA is most commonly associated with conditions that cause microvascular thrombosis, such as disseminated intravascular coagulation (DIC), vasculitis, hemangiosarcoma, and certain infectious diseases. The pathophysiology involves shearing of RBCs by fibrin strands or damaged endothelium, leading to intravascular hemolysis, release of free hemoglobin, and subsequent hemoglobinuria. MAHA can be a life-threatening condition requiring prompt diagnosis and aggressive management of the underlying cause.

The etiologies of MAHA in dogs and cats are diverse and include: 1) Disseminated intravascular coagulation (DIC) secondary to sepsis, pancreatitis, neoplasia, or trauma; 2) Vasculitis due to immune-mediated diseases (e.g., systemic lupus erythematosus), rickettsial infections (e.g., Ehrlichia canis, Anaplasma platys), or drug reactions; 3) Neoplasia, particularly hemangiosarcoma, which causes endothelial disruption and microthrombi formation; 4) Infectious agents that directly damage endothelium or induce DIC, such as heartworm (Dirofilaria immitis), bacterial sepsis (gram-negative endotoxemia), and viral infections (feline leukemia virus, feline immunodeficiency virus); 5) Heat stroke, which leads to endothelial injury and microthrombosis; 6) Severe burns or trauma; 7) Glomerulonephritis or other renal diseases that cause endothelial damage; 8) Inherited or acquired thrombotic microangiopathies, though rare in veterinary patients; 9) Intravascular devices (e.g., central venous catheters) that cause mechanical RBC fragmentation; 10) Severe iron deficiency anemia, which can produce schistocytes due to abnormal RBC membrane integrity. The underlying trigger must be identified to guide therapy.

MAHA is not a primary disease but a syndrome secondary to various underlying conditions. It can occur in dogs and cats of any age, breed, or sex, but the epidemiology reflects the underlying cause. For example, hemangiosarcoma is more common in older dogs, particularly breeds like Golden Retrievers, German Shepherds, and Labrador Retrievers. DIC secondary to sepsis is more common in young to middle-aged animals with infectious diseases. Rickettsial diseases (e.g., ehrlichiosis) are more prevalent in tropical and subtropical regions, and in dogs with tick exposure. Heat stroke is more common in hot climates and in brachycephalic breeds. There is no strong breed or sex predisposition for MAHA itself, but the underlying etiologies may have breed associations. The incidence of MAHA is not well documented, but it is considered an uncommon to rare presentation in general practice, often seen in referral settings.

The pathophysiology of MAHA involves a cascade of events: 1) Endothelial injury or activation, which can be caused by inflammatory cytokines, toxins, or direct invasion by pathogens. This leads to exposure of subendothelial collagen and tissue factor, activating the coagulation cascade. 2) Formation of microthrombi (fibrin strands) in small arterioles and capillaries. These fibrin strands create a meshwork that physically shears RBCs as they pass through, causing fragmentation and formation of schistocytes. 3) The fragmented RBCs are removed by the reticuloendothelial system, leading to anemia. Intravascular hemolysis releases free hemoglobin, which binds to haptoglobin; when haptoglobin is depleted, free hemoglobin is filtered by the kidneys, causing hemoglobinuria and potential renal tubular damage. 4) Thrombocytopenia occurs due to platelet consumption in microthrombi and/or immune-mediated destruction. 5) End-organ ischemia results from microvascular occlusion, leading to tissue hypoxia and dysfunction, particularly in the kidneys, brain, and gastrointestinal tract. 6) The release of pro-inflammatory cytokines and activation of complement can amplify the process, leading to a systemic inflammatory response syndrome (SIRS) and multi-organ dysfunction. The severity of MAHA depends on the extent of microthrombosis and the rapidity of onset.

Predisposing factors for MAHA include: 1) Underlying conditions that cause endothelial injury or hypercoagulability, such as sepsis, pancreatitis, neoplasia, trauma, and heat stroke. 2) Immune-mediated diseases that cause vasculitis, such as systemic lupus erythematosus or immune-mediated hemolytic anemia (IMHA) with concurrent DIC. 3) Infectious diseases that trigger DIC or directly damage endothelium, including ehrlichiosis, anaplasmosis, babesiosis, and heartworm disease. 4) Genetic predisposition to thrombotic disorders, though rare in veterinary medicine. 5) Administration of certain drugs that can induce immune-mediated vasculitis or thrombotic microangiopathy (e.g., cyclosporine, certain chemotherapeutic agents). 6) Presence of intravascular devices, such as central venous catheters, which can cause mechanical RBC fragmentation. 7) Severe iron deficiency, which can lead to abnormal RBC membrane rigidity and increased susceptibility to fragmentation. 8) Hyperadrenocorticism (Cushing's disease) or other conditions that cause hypercoagulability. 9) Obesity and advanced age, which are risk factors for thromboembolic disease. 10) Environmental factors such as high ambient temperature for heat stroke.

Clinical signs of MAHA are often acute and severe, reflecting the underlying cause and the degree of hemolysis and thrombosis. Common signs include: 1) Lethargy, weakness, and depression due to anemia and tissue hypoxia. 2) Pale mucous membranes, tachycardia, and tachypnea as compensatory responses to anemia. 3) Icterus (jaundice) due to increased bilirubin from hemolysis. 4) Hemoglobinuria (dark red or brown urine) due to intravascular hemolysis. 5) Petechiae, ecchymoses, or bleeding from other sites due to thrombocytopenia and DIC. 6) Fever, if infection or inflammation is present. 7) Signs of end-organ ischemia, such as acute kidney injury (oliguria, azotemia), neurological signs (seizures, ataxia, altered mentation), or gastrointestinal signs (vomiting, diarrhea, melena). 8) In cases of hemangiosarcoma, there may be a palpable abdominal mass, acute collapse due to hemorrhage, or signs of right-sided heart failure if the tumor involves the right atrium. 9) In cases of heat stroke, there may be hyperthermia, panting, and collapse. The clinical signs can progress rapidly to shock and death if not treated promptly.

Differential diagnoses for MAHA include: 1) Immune-mediated hemolytic anemia (IMHA): Both cause anemia and sometimes schistocytes, but IMHA typically has a positive direct Coombs test, spherocytes, and autoagglutination, whereas MAHA has schistocytes and often thrombocytopenia. 2) Microangiopathic hemolytic anemia due to DIC: This is a cause of MAHA, so it is not a differential but a subtype. 3) Hemolytic-uremic syndrome (HUS): Rare in animals, but can cause MAHA, thrombocytopenia, and acute kidney injury. 4) Babesiosis: Causes hemolytic anemia with intracellular parasites seen on blood smear, and can also cause DIC. 5) Heinz body hemolytic anemia: Caused by oxidative damage (e.g., onion toxicity, acetaminophen), with Heinz bodies on blood smear. 6) Iron deficiency anemia: Can cause schistocytes, but typically microcytic, hypochromic anemia with low serum iron and ferritin. 7) Myelophthisic anemia due to bone marrow neoplasia: May have schistocytes but also has leukoerythroblastic changes and cytopenias. 8) Vasculitis due to immune-mediated disease: Can cause MAHA, but also has other signs of systemic inflammation. 9) Sepsis with DIC: Can cause MAHA, but also has fever, hypotension, and evidence of infection. 10) Heat stroke: Can cause MAHA, but also has hyperthermia and multi-organ dysfunction. Definitive diagnosis requires a thorough workup including blood smear, coagulation panel, and specific tests for underlying causes.

The diagnostic approach to MAHA should be systematic: 1) Initial triage: Assess vital signs, mucous membrane color, and perfusion. If the animal is unstable, provide emergency stabilization (oxygen, IV fluids, blood transfusion if needed). 2) Complete blood count (CBC) with blood smear: Look for schistocytes, spherocytes, Heinz bodies, and parasites. Also assess platelet count. 3) Coagulation panel: Prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, D-dimer, and antithrombin III to evaluate for DIC. 4) Serum biochemistry panel: Evaluate for azotemia (renal ischemia), liver enzymes (hepatic ischemia), electrolytes, and acid-base status. 5) Urinalysis: Check for hemoglobinuria, proteinuria, and casts. 6) Direct Coombs test and autoagglutination to rule out IMHA. 7) Infectious disease testing: Depending on exposure, test for Ehrlichia, Anaplasma, Babesia, Leptospira, heartworm, and FeLV/FIV. 8) Imaging: Thoracic radiographs and abdominal ultrasound to look for neoplasia (e.g., hemangiosarcoma), pancreatitis, or other underlying causes. 9) If no cause is found, consider bone marrow aspiration to rule out primary bone marrow disease. 10) Advanced imaging (CT, MRI) if neurological signs are present. The diagnostic algorithm should be tailored to the most likely underlying cause based on signalment and history.

Laboratory findings in MAHA include: 1) Hematology: Anemia (often severe, with PCV < 20%), reticulocytosis (if chronic) or normal reticulocyte count (if acute), schistocytes on blood smear, thrombocytopenia (often < 50,000/µL), and sometimes leukocytosis due to inflammation. 2) Serum biochemistry: Elevated bilirubin (mainly unconjugated), elevated lactate dehydrogenase (LDH), decreased haptoglobin, elevated blood urea nitrogen (BUN) and creatinine (if renal ischemia), elevated liver enzymes (ALT, AST) if hepatic ischemia, and electrolyte imbalances (e.g., hyperkalemia if renal failure). 3) Coagulation panel: Prolonged PT and aPTT, decreased fibrinogen, elevated D-dimer, and decreased antithrombin III, consistent with DIC. 4) Urinalysis: Hemoglobinuria (positive for blood on dipstick but no RBCs on sediment), proteinuria, and granular casts. 5) Blood gas analysis: Metabolic acidosis due to lactic acidosis from tissue hypoxia. 6) Specific biomarkers: Elevated C-reactive protein (CRP) in inflammatory conditions, elevated troponin I if myocardial ischemia, and elevated SDMA if renal injury. 7) Serology/PCR: Positive for infectious agents if present. 8) Direct Coombs test: Usually negative, but may be positive if concurrent IMHA.

Imaging findings in MAHA are related to the underlying cause: 1) Thoracic radiographs: May show a heart base mass (hemangiosarcoma), pulmonary metastases, or signs of heart failure (cardiomegaly, pulmonary edema). 2) Abdominal ultrasound: May reveal splenic mass (hemangiosarcoma), hepatic nodules, pancreatitis (enlarged, hypoechoic pancreas), or evidence of thrombosis (e.g., in the caudal vena cava). 3) Echocardiography: If right atrial mass is suspected, echocardiography can identify a mass and assess for pericardial effusion. 4) CT or MRI: Useful for detecting brain lesions if neurological signs are present, or for staging neoplasia. 5) Doppler ultrasound: Can assess blood flow in organs and detect thrombosis. 6) Endoscopy: Not typically used, but may be indicated if gastrointestinal bleeding is suspected. Imaging is crucial for identifying the underlying etiology and guiding treatment.

Cytology and histopathology are important for diagnosing the underlying cause of MAHA: 1) Fine needle aspirate (FNA) of a splenic or hepatic mass may reveal neoplastic cells (e.g., hemangiosarcoma) or evidence of inflammation. 2) Bone marrow aspirate may show erythroid hyperplasia (if regenerative anemia) or myelophthisis (if neoplasia). 3) Histopathology of a biopsy from affected organs (e.g., spleen, liver, kidney) can confirm the presence of microthrombi, endothelial damage, or neoplasia. Special stains such as phosphotungstic acid hematoxylin (PTAH) can highlight fibrin. 4) In cases of vasculitis, biopsy may show leukocytoclastic vasculitis or fibrinoid necrosis of vessel walls. 5) If DIC is suspected, histopathology may reveal fibrin thrombi in small vessels of multiple organs. Cytology and histopathology are not always necessary but can be definitive in identifying the underlying disease.

Treatment of MAHA is primarily directed at the underlying cause, but supportive care is essential. 1) Emergency stabilization: Administer oxygen, IV fluids (crystalloids, e.g., Lactated Ringer's or Normosol-R, at shock doses 60-90 mL/kg in dogs, 40-60 mL/kg in cats, over 15-30 minutes, then reassess), and blood transfusion if PCV < 15-20% or if clinical signs of hypoxia. 2) Treat DIC: Address the underlying trigger, and consider anticoagulant therapy with heparin (unfractionated heparin 200-300 IU/kg IV loading dose, then 100-200 IU/kg SC q8h, or low molecular weight heparin e.g., enoxaparin 0.8 mg/kg SC q6-8h in dogs, 1 mg/kg SC q6-8h in cats) if thrombosis is documented. 3) If immune-mediated vasculitis is suspected, immunosuppressive doses of corticosteroids (e.g., prednisone 1-2 mg/kg PO q12h) may be indicated. 4) For infectious causes, specific antimicrobial therapy: Doxycycline (5-10 mg/kg PO q12h for 14-21 days) for rickettsial diseases, clindamycin (10-20 mg/kg PO q12h) for babesiosis, etc. 5) For hemangiosarcoma, surgical excision of the mass (e.g., splenectomy) and chemotherapy (e.g., doxorubicin 30 mg/m² IV q3 weeks) may be considered. 6) Supportive care: Gastroprotectants (e.g., omeprazole 1 mg/kg PO q12h), antiemetics (e.g., maropitant 1 mg/kg SC q24h), and nutritional support. 7) Monitor and manage complications such as acute kidney injury (fluid therapy, diuretics if oliguric), and neurological signs. 8) In severe cases, plasma transfusion may be considered to replace antithrombin III and other coagulation factors. Treatment must be aggressive and tailored to the individual patient.

The prognosis for MAHA is highly variable and depends on the underlying cause and the severity of the condition. If the underlying cause is treatable (e.g., rickettsial infection, heat stroke), the prognosis can be good with prompt therapy. However, if the cause is severe neoplasia (e.g., hemangiosarcoma) or advanced DIC with multi-organ failure, the prognosis is poor to grave. Negative prognostic indicators include: severe thrombocytopenia (<20,000/µL), marked azotemia, neurological signs, and lack of response to treatment within 24-48 hours. Mortality rates can be high, especially in cases of DIC and hemangiosarcoma. Early diagnosis and aggressive management of the underlying cause are critical for a favorable outcome. In cases where the underlying cause is controlled, the anemia and thrombocytopenia typically resolve within days to weeks.

Follow-up for MAHA should be structured based on the underlying cause and the patient's response to therapy. 1) Recheck CBC and platelet count every 24-48 hours initially to monitor for improvement or worsening. 2) Monitor coagulation parameters (PT, aPTT, D-dimer) every 24-48 hours until DIC resolves. 3) Recheck serum biochemistry and urinalysis to monitor renal and hepatic function. 4) If the patient is on immunosuppressive therapy, monitor for side effects and taper the dose gradually over weeks to months. 5) If the patient is on antimicrobial therapy, complete the full course and recheck for resolution of infection. 6) For neoplasia, follow-up imaging (ultrasound, radiographs) every 1-3 months to monitor for recurrence or metastasis. 7) Provide dietary recommendations (e.g., high-quality protein for recovery) and restrict exercise until the anemia resolves. 8) Long-term monitoring may be needed for chronic conditions such as immune-mediated disease or chronic kidney disease. The frequency of follow-up should be individualized based on the patient's condition.

Pearls: 1) Always examine a fresh blood smear for schistocytes in any anemic patient with thrombocytopenia. 2) MAHA is a syndrome, not a disease; always search for an underlying cause. 3) DIC is a common cause of MAHA; early recognition and treatment of DIC can improve outcomes. 4) In dogs with a splenic mass and MAHA, hemangiosarcoma is a top differential; consider splenectomy. 5) In cats, MAHA is less common but can occur with severe infections or neoplasia. Pitfalls: 1) Failing to differentiate MAHA from IMHA, as treatment differs (immunosuppression vs. treating the underlying cause). 2) Overlooking the possibility of DIC and not performing a coagulation panel. 3) Administering blood transfusions without addressing the underlying cause, which can worsen the condition. 4) Using heparin without monitoring coagulation parameters, leading to bleeding complications. 5) Delaying diagnostic imaging, which may miss a treatable neoplasm. 6) Not considering infectious diseases in endemic areas, leading to delayed antimicrobial therapy.

Drug protocols for MAHA are directed at the underlying cause and supportive care. 1) For DIC: Unfractionated heparin (UFH) at 200-300 IU/kg IV loading dose, then 100-200 IU/kg SC q8h; monitor aPTT to maintain 1.5-2 times baseline. Low molecular weight heparin (LMWH) e.g., enoxaparin at 0.8 mg/kg SC q6-8h in dogs, 1 mg/kg SC q6-8h in cats; monitor anti-Xa activity if available. 2) For immune-mediated vasculitis: Prednisone at 1-2 mg/kg PO q12h, tapering over 4-6 weeks. 3) For rickettsial infections: Doxycycline at 5-10 mg/kg PO q12h for 14-21 days. 4) For babesiosis: Clindamycin at 10-20 mg/kg PO q12h for 14 days, or imidocarb dipropionate at 5-6.6 mg/kg IM once, repeated in 2 weeks. 5) For hemangiosarcoma: Doxorubicin at 30 mg/m² IV q3 weeks, with cardiac monitoring. 6) For supportive care: IV fluids (e.g., Normosol-R at maintenance rates 40-60 mL/kg/day), blood transfusion (packed RBCs at 10-20 mL/kg over 4 hours), gastroprotectants (omeprazole 1 mg/kg PO q12h), antiemetics (maropitant 1 mg/kg SC q24h), and analgesics if needed (e.g., buprenorphine 0.01-0.02 mg/kg IV/IM q8-12h). 7) For acute kidney injury: Consider furosemide (1-2 mg/kg IV q8h) if oliguric, and mannitol (0.5-1 g/kg IV over 20 minutes) if anuric. 8) For sepsis: Broad-spectrum antibiotics (e.g., ampicillin 22 mg/kg IV q8h and enrofloxacin 10 mg/kg IV q24h) until culture results. All dosages should be adjusted for renal or hepatic impairment and monitored for adverse effects.

Evidence-based literature on MAHA in veterinary medicine is limited, but key studies include: 1) A retrospective study by Ettinger et al. (2017) on dogs with hemangiosarcoma and MAHA, which found that schistocytes were present in 50% of cases and were associated with a poorer prognosis. 2) A study by Goggs et al. (2014) on DIC in dogs, which highlighted the importance of early diagnosis and treatment with heparin, showing improved survival in dogs with DIC when treated with LMWH compared to UFH. 3) A consensus statement from the ACVIM (2019) on the diagnosis and treatment of immune-mediated hemolytic anemia, which emphasizes the need to differentiate MAHA from IMHA. 4) A study by DeLay et al. (2018) on heat stroke in dogs, which documented MAHA as a common complication and recommended aggressive fluid therapy and cooling. 5) A review by Herring et al. (2020) on thrombotic microangiopathies in dogs and cats, which summarized the etiologies and treatment options. 6) A study by Kohn et al. (2016) on ehrlichiosis and anaplasmosis, which showed that doxycycline therapy resolved MAHA in most cases. These studies provide evidence for the diagnostic and therapeutic approaches outlined above, but more research is needed to establish standardized protocols for MAHA in veterinary patients.